CompletedPhase 2NCT00276523

PEG-interferon Alfa-2b in Treating Patients With Stage II, Stage III, or Stage IV Head and Neck Cancer That Can Be Removed By Surgery

Studying Squamous cell carcinoma of oral cavity and lip

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
M.D. Anderson Cancer Center
Principal Investigator
Roy S. Herbst, MD, PhD
M.D. Anderson Cancer Center
Intervention
PEG-interferon alfa-2b(biological)
Enrollment
3 enrolled
Eligibility
18 years · All sexes
Timeline
20042006

Study locations (1)

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00276523 on ClinicalTrials.gov

Other trials for Squamous cell carcinoma of oral cavity and lip

Additional recruiting or active studies for the same condition.

See all trials for Squamous cell carcinoma of oral cavity and lip

← Back to all trials